What does EUROFINS PHARMACEUTICAL PRODUCT TESTING BELGIUM do?

EUROFINS PHARMACEUTICAL PRODUCT TESTING BELGIUM is a testing and inspection body in Brugge. Public Limited, started on 9 September 1988, 2 establishments.

What is the address of EUROFINS PHARMACEUTICAL PRODUCT TESTING BELGIUM?

The registered office of EUROFINS PHARMACEUTICAL PRODUCT TESTING BELGIUM is located at Lieven Bauwensstraat 6, 8200 Brugge.

Is EUROFINS PHARMACEUTICAL PRODUCT TESTING BELGIUM still active?

Yes. According to the CBE (17 September 2026) EUROFINS PHARMACEUTICAL PRODUCT TESTING BELGIUM is active, legal situation “Normale toestand”, started on 9 September 1988.

Is EUROFINS PHARMACEUTICAL PRODUCT TESTING BELGIUM registered on Peppol?

Yes, EUROFINS PHARMACEUTICAL PRODUCT TESTING BELGIUM is registered on the Peppol network with ID 0208:0435237515.

Who are the directors of EUROFINS PHARMACEUTICAL PRODUCT TESTING BELGIUM?

According to the 2025 annual accounts, the directors of EUROFINS PHARMACEUTICAL PRODUCT TESTING BELGIUM are: Marco Antonio Baeli.

Is EUROFINS PHARMACEUTICAL PRODUCT TESTING BELGIUM a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 9 September 1988; 5 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account; 2 establishments in the CBE.

How much profit did EUROFINS PHARMACEUTICAL PRODUCT TESTING BELGIUM make in 2025?

EUROFINS PHARMACEUTICAL PRODUCT TESTING BELGIUM posted a profit after taxes of € 103,882 in financial year 2025.

What is the revenue of EUROFINS PHARMACEUTICAL PRODUCT TESTING BELGIUM?

As a small company, EUROFINS PHARMACEUTICAL PRODUCT TESTING BELGIUM is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 1,889,206.

How much does an employee at EUROFINS PHARMACEUTICAL PRODUCT TESTING BELGIUM earn?

The average wage cost per full-time employee at EUROFINS PHARMACEUTICAL PRODUCT TESTING BELGIUM was € 78,300 in 2025: staff costs of € 1.6 million for 20 FTE, according to the annual account at the National Bank. That is the employer's cost, not net pay.

EUROFINS PHARMACEUTICAL PRODUCT TESTING BELGIUM (Public Limited)

Q: What is the enterprise number of EUROFINS PHARMACEUTICAL PRODUCT TESTING BELGIUM?

The enterprise number of EUROFINS PHARMACEUTICAL PRODUCT TESTING BELGIUM is BE0435237515.

Q: When was EUROFINS PHARMACEUTICAL PRODUCT TESTING BELGIUM founded?

EUROFINS PHARMACEUTICAL PRODUCT TESTING BELGIUM was founded on 9 September 1988.

Dossier EUROFINS PHARMACEUTICAL PRODUCT TESTING BELGIUM, printed on 17 September 2026 from databakkes.be/en/0435237515/eurofins-pharmaceutical-product-testing-belgium. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Shrinking team NBB

FTE fell two years in a row, from 22.7 to 20.

Financials

Financial year 2025

EUROFINS PHARMACEUTICAL PRODUCT TESTING BELGIUM from Brugge, company number BE0435237515, closed financial year 2025 with a result of € 103,882 after tax. For that financial year EUROFINS PHARMACEUTICAL PRODUCT TESTING BELGIUM recorded a gross margin of € 1.9 million and equity of € 816,310. Compared with financial year 2024, the result moved from € 370,991 to € 103,882. The company is profitable. The company holds a healthy buffer. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on July 17, 2026.

What it is worth Healthy

€ 816,310

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Healthy

€ 103,882

▼ 72% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 677,243

▼ 20% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Pays out

€ 103,882 paid out

100 % of the profit went to the shareholders, the rest stayed in the company.

People and assets in 2025

Full-time equivalents

▼ 2 vs 2024

Average over the fiscal year, from the social balance sheet.

Wage cost

€ 1.6 million

▼ 8% vs 2024

€ 78,300 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 30,517

▼ 20% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt ≈ 73 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 1 million

€ 14,396 is repaid this year. At this pace the long-term loan is gone in ≈ 73 years.

Owed to suppliers

€ 584,864

▲ 3% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 376,094

▼ 3% vs 2024

Taxes, VAT and social contributions still to pay.

Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 2,644,363 Gross margin 2022: € 2,644,363 First fiscal year in the series	€ 3,052,097 Gross margin 2023: € 3,052,097 ▲ 15% vs 2022 (€ 2,644,363) Favourable step	€ 2,410,982 Gross margin 2024: € 2,410,982 ▼ 21% vs 2023 (€ 3,052,097) Unfavourable step	€ 1,889,206 Gross margin 2025: € 1,889,206 ▼ 22% vs 2024 (€ 2,410,982) Unfavourable step	▼ 22%
Profit after taxes	€ 822,736 Profit after taxes 2022: € 822,736 First fiscal year in the series	€ 457,069 Profit after taxes 2023: € 457,069 ▼ 44% vs 2022 (€ 822,736) Unfavourable step	€ 370,991 Profit after taxes 2024: € 370,991 ▼ 19% vs 2023 (€ 457,069) Unfavourable step	€ 103,882 Profit after taxes 2025: € 103,882 ▼ 72% vs 2024 (€ 370,991) Unfavourable step	▼ 72%
Equity	€ 816,310 Equity 2022: € 816,310 First fiscal year in the series	€ 816,310 Equity 2023: € 816,310 Unchanged (€ 816,310) Unchanged	€ 816,310 Equity 2024: € 816,310 Unchanged (€ 816,310) Unchanged	€ 816,310 Equity 2025: € 816,310 Unchanged (€ 816,310) Unchanged
Total debts	€ 4,186,199 Total debts 2022: € 4,186,199 First fiscal year in the series	€ 3,000,344 Total debts 2023: € 3,000,344 ▼ 28% vs 2022 (€ 4,186,199) Favourable step	€ 2,687,709 Total debts 2024: € 2,687,709 ▼ 10% vs 2023 (€ 3,000,344) Favourable step	€ 2,396,158 Total debts 2025: € 2,396,158 ▼ 11% vs 2024 (€ 2,687,709) Favourable step	▼ 11%
Cash	€ 262,891 Cash 2022: € 262,891 First fiscal year in the series	€ 507,854 Cash 2023: € 507,854 ▲ 93% vs 2022 (€ 262,891) Favourable step	€ 845,258 Cash 2024: € 845,258 ▲ 66% vs 2023 (€ 507,854) Favourable step	€ 677,243 Cash 2025: € 677,243 ▼ 20% vs 2024 (€ 845,258) Unfavourable step	▼ 20%
Land & buildings	€ 1,180,166 Land & buildings 2022: € 1,180,166 First fiscal year in the series	€ 547,482 Land & buildings 2023: € 547,482 ▼ 54% vs 2022 (€ 1,180,166) Unchanged	€ 479,803 Land & buildings 2024: € 479,803 ▼ 12% vs 2023 (€ 547,482) Unchanged	€ 415,102 Land & buildings 2025: € 415,102 ▼ 13% vs 2024 (€ 479,803) Unchanged	▼ 13%
Retained profit	€ 371,310 Retained profit 2022: € 371,310 First fiscal year in the series	€ 371,310 Retained profit 2023: € 371,310 Unchanged (€ 371,310) Unchanged	€ 371,310 Retained profit 2024: € 371,310 Unchanged (€ 371,310) Unchanged	€ 371,310 Retained profit 2025: € 371,310 Unchanged (€ 371,310) Unchanged
Dividend	€ 822,736 Dividend 2022: € 822,736 First fiscal year in the series	€ 457,069 Dividend 2023: € 457,069 ▼ 44% vs 2022 (€ 822,736) Unchanged	€ 370,991 Dividend 2024: € 370,991 ▼ 19% vs 2023 (€ 457,069) Unchanged	€ 103,882 Dividend 2025: € 103,882 ▼ 72% vs 2024 (€ 370,991) Unchanged	▼ 72%
Bank debt	€ 1,050,563 Bank debt 2022: € 1,050,563 First fiscal year in the series	€ 1,047,735 Bank debt 2023: € 1,047,735 Unchanged (€ 1,050,563) Favourable step	€ 1,046,213 Bank debt 2024: € 1,046,213 Unchanged (€ 1,047,735) Favourable step	€ 1,046,213 Bank debt 2025: € 1,046,213 Unchanged (€ 1,046,213) Unfavourable step
Balance sheet total	€ 5,002,509 Balance sheet total 2022: € 5,002,509 First fiscal year in the series	€ 3,816,655 Balance sheet total 2023: € 3,816,655 ▼ 24% vs 2022 (€ 5,002,509) Unchanged	€ 3,504,020 Balance sheet total 2024: € 3,504,020 ▼ 8% vs 2023 (€ 3,816,655) Unchanged	€ 3,212,468 Balance sheet total 2025: € 3,212,468 ▼ 8% vs 2024 (€ 3,504,020) Unchanged	▼ 8%
Employees (FTE)	19.9 Employees (FTE) 2022: 19.9 First fiscal year in the series	22.7 Employees (FTE) 2023: 22.7 ▲ 2.8 vs 2022 (19.9) Unchanged	22 Employees (FTE) 2024: 22 ▼ 0.7 vs 2023 (22.7) Unchanged	20 Employees (FTE) 2025: 20 ▼ 2 vs 2024 (22) Unchanged	▼ 2

Key figures of EUROFINS PHARMACEUTICAL PRODUCT TESTING BELGIUM, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to EUROFINS PHARMACEUTICAL PRODUCT TESTING BELGIUM?

What happened at EUROFINS PHARMACEUTICAL PRODUCT TESTING BELGIUM in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Jul 17, 2026 New annual accounts for financial year 2025: profit of € 103,882 (▼ 72% vs 2024). Source: NBB ↗
2026 Marco Antonio Baeli stepped down as director. NBB
2020 Marco Antonio Baeli became a director. NBB
Apr 1, 2014 New establishment in Nazareth-De Pinte. KBO
Sep 28, 1988 New establishment in Brugge. KBO
Sep 9, 1988 Start of the company according to the CBE. KBO

In short

From € 822,736 profit in 2022 to € 103,882 profit in 2025.

Paid € 667,556 in corporate taxes since 2022.

Best year ever: 2022, with € 822,736 profit.

On average € 94,500 of value added per employee in 2025.

Original PDFs at the National Bank ↗

A new publication or filing at EUROFINS PHARMACEUTICAL PRODUCT TESTING BELGIUM? We notify you, reason included.

Follow EUROFINS PHARMACEUTICAL PRODUCT TESTING BELGIUM

Databakkes Pro

Know what changes at your customers, suppliers and competitors. Without reading an annual account.

Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.

Yes, I want that

See what a followed company gets: the De Lijn dossier

Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.

My folder 3 companies

De Lijn 8 June 2026 New annual account 2025

filed on 8 June 2026

What was left

€ 20 k ▼ 91%
Money in the bank

€ 178 k ▼ 98%

Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit

Real filings at the National Bank

Management

Directors

According to the 2025 annual accounts

Marco Antonio Baeli

Director

since 2020 · until 2026

Establishments

Establishment units

Physical locations of this company

Registered office

Lieven Bauwensstraat 6

8200 Brugge

2.229.221.138

Venecoweg 5

9810 Nazareth-De Pinte

Active since 1 April 2014

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 3 companies are registered at this address.

All companies at this address →

Villers le Bouillet Rue le Marais Real Estate

€ 233,924 gross margin · 2025

Eurofins NSC Belgium

€ 712,542 gross margin · 2025

EUROFINS FORENSICS BELGIUM

€ 3.2 million gross margin · 2025

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0435.237.515

VAT number

BE 0435.237.515

Registered office

Lieven Bauwensstraat 6, 8200 Brugge

Names & denominations

EUROFINS PHARMACEUTICAL PRODUCT TESTING BELGIUM

Enterprise type

Rechtspersoon

Legal form

Public limited company

Legal situation

Normale toestand

Start date

9 September 1988

Peppol

Active · Active since 3 Dec 2025

Activities · NACE

Overige technische testen en toetsen

Technische testen en analyses

Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied

Speur- en ontwikkelingswerk op natuurwetenschappelijk gebied